MGMT and central nervous system cancer: On the other hand, TERT promoter mutation was an indicator of worse outcome in MGMT-unmethylated (MGMT-unmeth) gliomas (HR = 1.86; 95% CI = 1.54–2.26; p-value < 0.001) (Fig. 2b).